| Item Type | Name |
|
Concept
|
Mesothelioma
|
|
Concept
|
Pleural Effusion, Malignant
|
|
Academic Article
|
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
|
|
Academic Article
|
Malignant pleural mesothelioma.
|
|
Academic Article
|
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.
|
|
Academic Article
|
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
|
|
Academic Article
|
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
|
|
Academic Article
|
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
|
|
Academic Article
|
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
|
|
Academic Article
|
Current state and future directions of pleural mesothelioma imaging.
|
|
Academic Article
|
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
|
|
Academic Article
|
The emerging role of pemetrexed for the treatment of malignant mesothelioma.
|
|
Academic Article
|
Protein kinase C beta in malignant pleural mesothelioma.
|
|
Academic Article
|
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
|
|
Academic Article
|
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
|
|
Academic Article
|
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
|
|
Academic Article
|
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
|
|
Academic Article
|
Antiangiogenic therapies for mesothelioma.
|
|
Academic Article
|
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
|
|
Academic Article
|
Variability in mesothelioma tumor response classification.
|
|
Academic Article
|
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
|
|
Academic Article
|
Malignant pleural mesothelioma: an update on biomarkers and treatment.
|
|
Academic Article
|
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
|
|
Academic Article
|
Systemic treatments for mesothelioma: standard and novel.
|
|
Academic Article
|
Malignant pleural mesothelioma.
|
|
Academic Article
|
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
|
|
Academic Article
|
Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication.
|
|
Academic Article
|
Update on malignant pleural mesothelioma.
|
|
Academic Article
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Robust data: the essential foundation of a revised staging system for pleural mesothelioma.
|
|
Academic Article
|
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
|
|
Academic Article
|
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
|
|
Academic Article
|
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
|
|
Academic Article
|
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.
|
|
Academic Article
|
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
|
|
Academic Article
|
The cancer and leukemia group B respiratory committee.
|
|
Academic Article
|
Optimization of response classification criteria for patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Role of protein kinase C ? and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
|
|
Academic Article
|
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.
|
|
Academic Article
|
Computerized segmentation and measurement of malignant pleural mesothelioma.
|
|
Academic Article
|
Surgery for mesothelioma? The debate continues.
|
|
Academic Article
|
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
|
|
Academic Article
|
Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma.
|
|
Academic Article
|
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
|
|
Academic Article
|
The role of gemcitabine in the treatment of malignant mesothelioma.
|
|
Academic Article
|
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
|
Academic Article
|
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma.
|
|
Academic Article
|
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
|
|
Academic Article
|
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
|
|
Academic Article
|
MARS: a sense of perspective and an inconvenient truth.
|
|
Academic Article
|
Peritoneal mesothelioma: the site of origin matters.
|
|
Academic Article
|
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
|
|
Academic Article
|
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
|
|
Academic Article
|
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
|
|
Academic Article
|
Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Variability of tumor area measurements for response assessment in malignant pleural mesothelioma.
|
|
Academic Article
|
Radiologic-pathologic correlation of mesothelioma tumor volume.
|
|
Academic Article
|
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly.
|
|
Academic Article
|
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.
|
|
Academic Article
|
208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial.
|
|
Academic Article
|
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
|
|
Academic Article
|
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
|
|
Academic Article
|
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Immunological effects of the TGF?-blocking antibody GC1008 in malignant pleural mesothelioma patients.
|
|
Academic Article
|
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.
|
|
Academic Article
|
Amount of Epithelioid Differentiation Is?a?Predictor of Survival in Malignant Pleural?Mesothelioma.
|
|
Academic Article
|
The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma.
|
|
Academic Article
|
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
|
|
Academic Article
|
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
|
|
Academic Article
|
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
|
|
Academic Article
|
A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM).
|
|
Academic Article
|
A phase 2 clinical trial of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM).
|
|
Academic Article
|
Development of response criteria for mesothelioma based on a mathematical model.
|
|
Academic Article
|
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
|
|
Academic Article
|
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
|
|
Academic Article
|
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary.
|
|
Academic Article
|
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
|
|
Academic Article
|
Reply to D. de Fonseka et al.
|
|
Academic Article
|
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
|
|
Academic Article
|
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
|
|
Academic Article
|
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
|
|
Academic Article
|
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
|
|
Academic Article
|
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
|
|
Academic Article
|
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
|
|
Academic Article
|
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Reply to K. Masuda et al.
|
|
Academic Article
|
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.
|
|
Academic Article
|
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
|
|
Academic Article
|
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
|
|
Academic Article
|
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
|
|
Academic Article
|
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.
|
|
Academic Article
|
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
|
|
Academic Article
|
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
|
|
Academic Article
|
Understanding the new therapeutic options for mesothelioma.
|
|
Academic Article
|
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
|
|
Academic Article
|
Systemic Therapy for Mesothelioma: Turning the Corner.
|
|
Academic Article
|
The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.
|
|
Academic Article
|
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
|
|
Academic Article
|
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.
|
|
Academic Article
|
A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database.
|